Patents Assigned to Stanford University Medical Center
  • Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
    Publication number: 20040214775
    Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
    Type: Application
    Filed: April 8, 2004
    Publication date: October 28, 2004
    Applicants: Neurocrine Biosciences, Inc., Stanford University Medical Center
    Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
  • Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
    Patent number: 6740638
    Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: May 25, 2004
    Assignees: Neurocrine Biosciences, Inc., Stanford University Medical Center
    Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
  • Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
    Patent number: 6489299
    Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: December 3, 2002
    Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.
    Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
  • Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
    Patent number: 6369033
    Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: April 9, 2002
    Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.
    Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur